<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000793873">
  <TermName>Mektovi</TermName>
  <TermPronunciation>(mek-TOH-vee)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>
      A drug used with encorafenib to treat melanoma that has spread or cannot be removed by surgery and has a certain mutation (change) in the 
      <GeneName>BRAF</GeneName>
       gene. It is also being studied in the treatment of other types of cancer. Mektovi blocks proteins called MEK1 and MEK2, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called binimetinib.
    </DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000795174" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Mektovi&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000795173" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Mektovi&quot;" language="es" id="_4"/>
  <SpanishTermName>Mektovi</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>
      Medicamento que se usa con encorafenib para el tratamiento del melanoma que se diseminó o que no se puede extirpar con cirugía, y que tiene cierta mutación (cambio) en el gen 
      <GeneName>BRAF</GeneName>
      . También está en estudio para el tratamiento de otros tipos de cáncer. Mektovi bloquea las proteínas MEK1 y MEK2, lo que quizás ayude a evitar la multiplicación de células cancerosas. Es un tipo de inhibidor de cinasas. También se llama binimetinib.
    </DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2018-07-16</DateFirstPublished>
  <DateLastModified>2021-09-28</DateLastModified>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000793920" url="/about-cancer/treatment/drugs/binimetinib">Binimetinib</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
